Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions (Q37965553)

26 August 2017

title

Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions (English)

1 reference

adaptive radiation therapy

26 August 2017

main subject

0 references

author

Adam P. Dicker

8

1 reference

26 August 2017

Sarah Hegarty

6

0 references

Xinglei Shen

Xinglei Shen

1

0 references

Nicholas G Zaorsky

Nicholas G Zaorsky

2

0 references

Timothy N Showalter

Timothy N Showalter

9

0 references

Mark V Mishra

3

Mark V Mishra

1 reference

26 August 2017

Kathleen A Foley

4

1 reference

26 August 2017

Terry Hyslop

5

1 reference

26 August 2017

Laura T Pizzi

7

1 reference

26 August 2017

language of work or name

English

0 references

publication date

1 January 2012

1 reference

26 August 2017

1 reference

26 August 2017

volume

8

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

37-54

1 reference

Can it work? Does it work? Is it worth it? The testing of healthcareinterventions is evolving

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

The promise of comparative effectiveness research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Observational methods in comparative effectiveness research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Comparative effectiveness research and personalized medicine: catalyzing or colliding?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

The role of observational investigations in comparative effectiveness research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Grading quality of evidence and strength of recommendations for diagnostic tests and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Health Reform’s Tortuous Route To The Patient-Centered Outcomes Research Institute

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Using science to improve the nation's health system: NIH's commitment to comparative effectiveness research.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

New US centre to boost comparative health research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Projections of the cost of cancer care in the United States: 2010-2020.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Treatment decisions for localized prostate cancer: asking men what's important

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Time trends and local variation in primary treatment of localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Long-term survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Limits of observational data in determining outcomes from cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Active surveillance for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Patient acceptance of active surveillance as a treatment option for low-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Cost implications of the rapid adoption of newer technologies for treating prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Proton radiation in the management of localized cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Hazards of dose escalation in prostate cancer radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

A comparison of conformal and intensity modulated treatment planning techniques for early prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Studying radiation therapy using SEER-Medicare-linked data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Proton therapy for prostate cancer: the initial Loma Linda University experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Late gastrointestinal toxicities following radiation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

The dosimetric quality of brachytherapy implants in patients with small prostate volume depends on the experience of the brachytherapy team.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Proton beam therapy and the convoluted pathway to incorporating emerging technology into routine medical care in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Projecting the clinical benefits of adjuvant radiotherapy versus observation and selective salvage radiotherapy after radical prostatectomy: a decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Improving the reporting of pragmatic trials: an extension of the CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Pragmatic randomised controlled trial of preferred intensity exercise in women living with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Adaptive design methods in clinical trials - a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Use of propensity score technique to account for exposure-related covariates: an example and lesson

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Preference-based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Comparative effectiveness research methods: symposium overview and summary.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

American Joint Committee on Cancer prognostic factors consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Parameters for treatment decisions for salvage radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Multiple structural and functional abnormalities in the p450 aromatase expressing transgenic male mice are ameliorated by a p450 aromatase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Perspective and desire in comparative effectiveness research: the relative unimportance of mere preferences, the central importance of context.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Comparative effectiveness research and medical informatics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Radiation dose-volume effects in radiation-induced rectal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Analysis of pathologic extent of disease for clinically localized prostate cancer after radical prostatectomy and subsequent use of adjuvant radiation in a national cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Provider Case Volume and Outcomes Following Prostate Brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.11.131

21 January 2018

Identifiers

DOI

10.2217/FON.11.131

1 reference

26 August 2017

1 reference